Back to results
US 9,850,542 B2Granted
Gene signature to predict homologous recombination (HR) deficient cancer
AssigneeBoard of Regents, The University of Texas System
InventorsChun-Jen Lin, Guang Peng, Shiaw-Yih Lin, Gordon B. Mills
Life of this patent
Estimating the term…
Abstract
Methods for identifying and treating cancers that are homologous recombination (HR)-repair defective. In some aspects, HR defective cancers are treated with a PARP inhibitor therapy. Methods for sensitizing cancers to a PARP inhibitor therapy are also provided.
Claims8
A method of treating ovarian cancer in a cancer patient in need thereof, comprising:
- (a) determining the expression levels of BBOX1, C5orf41, CHEK1, DEPDC1, DLGAP5, FAM43A, FOXO3, HSD11B2, PLCD1, PPL, PROS1, SDCBP2, SERTAD4, SLC45A3, and TMEM158 in a sample of said patient's cancer;
- (b) selecting a patient wherein the expression levels of CHEK1, DEPDC1, SERTAD4, SLC45A3, and TMEM158 are downregulated compared to a non-cancerous sample and the expression levels of BBOX1, FAM43A, FOXO3, HSD11B2, PPL, PROS1, and SDCBP2 are upregulated compared to a non-cancerous sample;
- and
- (c) administering olaparib to said selected patient to treat said ovarian cancer.
1 more element
Dependencies are inferred from the claim text.